CRISPR Therapeutics
NASDAQ · CRSP·Zug, Switzerland·Mid-cap·Approved
Gene-editing biopharma developing CRISPR/Cas9 therapies. Co-developed CASGEVY (exa-cel) with Vertex — first CRISPR-based therapy approved (sickle cell disease, beta-thalassemia). Pipeline includes allogeneic CAR-T (CTX112), in vivo cardiovascular (CTX310/320), and T1D programs.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| CRISPR Therapeutics J.P. Morgan 2026 | JPM Healthcare | January 13, 2026 | 35 |